Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

被引：7

作者：

Touzeau, Cyrille ^{[1
]}

Perrot, Aurore ^{[2
]}

Hulin, Cyrille ^{[3
]}

Manier, Salomon ^{[4
]}

Macro, Margaret ^{[5
]}

Chretien, Marie-Lorraine ^{[6
]}

Karlin, Lionel ^{[7
]}

Decaux, Olivier ^{[8
]}

Jacquet, Caroline ^{[9
]}

Tiab, Mourad ^{[10
]}

Leleu, Xavier ^{[11
]}

Corre, Jill ^{[12
]}

Jobert, Alexandra ^{[13
]}

Planche, Lucie ^{[14
]}

Avet-Loiseau, Herve ^{[15
]}

Moreau, Philippe ^{[16
]}

机构：

[1] Ctr Hosp Univ Nantes, Nantes, France

[2] CRCT, Toulouse, France

[3] Ctr Hosp Univ Bordeaux, Pessac, France

[4] Ctr Hosp Univ Hop Huriez, Lille, France

[5] Hop Cote Nacre, Caen, France

[6] CHU Dijon, Dijon, France

[7] CH Lyon Sud, Pierre Benite, France

[8] Ctr Hosp Univ Rennes Hop Pontchaillou, Rennes, France

[9] CHU Nancy, Vandoeuvre Les Nancy, France

[10] Ctr Hosp Dept, La Roche Sur Yon 9, France

[11] Serv Dhematol & Therapie Cellulaire, Poitiers, France

[12] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[13] Ctr Hosp Univ, Nantes, France

[14] CHU Nantes, Nantes, France

[15] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[16] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174044

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyeLome (IFM) Krd Phase II Study
Roussel, Murielle
Lauwers-Cances, Valerie
Robillard, Nelly
Belhadj, Karim
Facon, Thierry
Garderet, Laurent
Escoffre, Martine
Pegourie, Brigitte
Benboubker, Lotfi
Caillot, Denis
Fohrer, Cecile
Moreau, Philippe
Leleu, Xavier
Avet-Loiseau, Herve
Attal, Michel
BLOOD, 2016, 128 (22)
[32] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
O'Donnell, Elizabeth K.
Mo, Clifton C.
Yee, Andrew J.
Nadeem, Omar
Branagan, Andrew R.
Laubach, Jacob P.
Gammon, Marilyn T.
Lively, Kathleen J.
Packer, Lisette
Harrington, Cynthia C.
Agyemang, Emerentia
Spillane, Kerry
LaStofka, Brenton
Rosenblatt, Jacalyn
Raje, Noopur S.
Richardson, Paul G.
BLOOD, 2021, 138
[33] THE QUADRUPLET COMBINATION OF CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE, AND DEXAMETHASONE IS SAFE AND WELL TOLERATED AS INDUCTION THERAPY FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MYELOMA PATIENTS
Pawlyn, C.
Davies, F.
Cairns, D.
Collett, C.
Jones, J.
Kaiser, M.
Chalmers, A.
Striha, A.
Milligan, D.
Lindsay, J.
Chapman, C.
Allotey, D.
Shafeek, S.
Karunanithi, K.
Cook, G.
Russell, N.
Drayson, M.
Owen, R.
Gregory, W.
Jackson, G.
Morgan, G.
HAEMATOLOGICA, 2015, 100 : 152 - 152
[34] Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Mateos, Maria-Victoria
Martinez-Lopez, Joaquin
Rodriguez Otero, Paula
Gonzalez-Calle, Veronica
Gonzalez, Marta Sonia
Oriol, Albert
Gutierrez, Norma C.
Rios-Tamayo, Rafael
Rosinol, Laura
Alvarez Rivas, Miguel Angel
Bargay, Joan
Gonzalez-Rodriguez, Ana Pilar
Alegre, Adrian
Escalante, Fernando
Inigo Rodriguez, Maria Belen
de la Rubia, Javier
Teruel, Ana Isabel
de Arriba, Felipe
Palomera, Luis
Hernandez, Miguel T.
Lopez Jimenez, Javier
Reinoso-Segura, Marta
Garcia Mateo, Aranzazu
Ocio, Enrique M.
Paiva, Bruno
Puig, Noemi
Cedena, M. Teresa
Blade, Joan
Lahuerta, Juan Jose
San-Miguel, Jesus F.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (27)
[35] All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
Touzeau, Cyrille
Perrot, Aurore
Roussel, Murielle
Karlin, Lionel
Benboubker, Lotfi
Jacquet, Caroline
Mohty, Mohamad
Facon, Thierry
Manier, Salomon
Chretien, Marie-Lorraine
Tiab, Mourad
Hulin, Cyrille
Leleu, Xavier
Loiseau, Herve Avet
Dejoie, Thomas
Planche, Lucie
Attal, Michel
Moreau, Philippe
HAEMATOLOGICA, 2022, 107 (07) : 1693 - 1697
[36] Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study
Anderson, K. C.
Weller, E.
Lonial, S.
Jakubowiak, A. J.
Jagannath, S.
Raje, N. S.
Avigan, D.
Knight, R. D.
Esseltine, D.
Richardson, P. G.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[37] A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
O'Donnell, Elizabeth K.
Suman, Vera Jean
Geyer, Susan M.
Nadeem, Omar
Dinner, Shira
Yee, Andrew J.
Laubach, Jacob P.
Mo, Clifton C.
Tuchman, Sascha A.
Donadio, Kristen
Sinclair, Sarah
Raje, Noopur S.
Richardson, Paul G.
BLOOD, 2021, 138
[38] Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma
Leypoldt, Lisa B.
Tichy, Diana
Besemer, Britta
Hanel, Mathias
Raab, Marc S.
Mann, Christoph
Munder, Markus
Reinhardt, Hans Christian
Nogai, Axel
Gorner, Martin
Ko, Yon-Dschun
de Wit, Maike
Salwender, Hans
Scheid, Christof
Graeven, Ullrich
Peceny, Rudolf
Staib, Peter
Dieing, Annette
Einsele, Hermann
Jauch, Anna
Hundemer, Michael
Zago, Manola
Pozek, Ema
Benner, Axel
Bokemeyer, Carsten
Goldschmidt, Hartmut
Weisel, Katja C.
FUTURE ONCOLOGY, 2024,
[39] Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients
Korde, Neha
Zingone, Adriana
Kwok, Mary
Manasanch, Elisabet E.
Costello, Rene
Zuchlinski, Diamond
Mulquin, Marcia
Maric, Irina
Calvo, Katherine R.
Braylan, Raul C.
Yuan, Constance
Tembhare, Prashant Ramesh
Stetler-Stevenson, Maryalice
Arthur, Diane C.
Raffeld, Mark
Xi, Liqiang
Choyke, Peter
Kurdziel, Karen
Lindenberg, Liza
Steinberg, Seth M.
Roschewski, Mark
Landgren, Ola
BLOOD, 2012, 120 (21)
[40] Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study
Roussel, Murielle
Avet-Loiseau, Herve
Moreau, Philippe
Huynh, Anne
Benboubker, Lotfi
Hulin, Cyrille
Marit, Gerald
Leleu, Xavier
Pegourie, Brigitte
Fruchart, Christophe
Caillot, Denis
Stoppa, Anne-Marie
Facon, Thierry
Harousseau, Jean-Luc
Attal, Michel
BLOOD, 2010, 116 (21) : 274 - 275

← 1 2 3 4 5 →